BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
- None.
- None.
Insights
The collaboration between BriaCell Therapeutics and The University of Texas MD Anderson Cancer Center represents a significant step in the clinical development of personalized cancer vaccines. The development of Bria-OTS+ and Bria-PROS+ could potentially revolutionize the treatment paradigm for patients with advanced breast and prostate cancer. These vaccines aim to stimulate the patient's immune system to recognize and attack cancer cells more effectively. The personalized aspect of these vaccines is particularly noteworthy as it suggests a tailored approach to immunotherapy, which has been a growing trend in cancer treatment.
From a clinical perspective, the involvement of a reputable institution such as MD Anderson could enhance the credibility and the rigor of the clinical trials, potentially increasing the likelihood of successful outcomes. Furthermore, if these vaccines prove to be effective, they could reduce the reliance on more invasive treatments such as chemotherapy and radiation, which often come with significant side effects.
The announcement of the agreement for advancing the clinical development of BriaCell's cancer vaccines is poised to have a notable impact on the company's financial prospects. As a clinical-stage biotechnology company, BriaCell's valuation heavily depends on the progress and potential success of its product pipeline. The partnership with a leading cancer treatment group like MD Anderson can be seen as a vote of confidence in BriaCell's technology and may positively influence investor sentiment.
Moreover, the advancement of these vaccines into later stages of clinical trials could lead to significant milestones payments, increased funding opportunities and partnerships. Investors should monitor the progress of these trials closely, as positive results could lead to substantial stock price appreciation, while any setbacks might have the opposite effect. It's also important to consider the competitive landscape of cancer immunotherapies and how BriaCell's approach differentiates itself in terms of efficacy, safety and cost.
The strategic agreement to advance Bria-OTS+ and Bria-PROS+ into further clinical development is a critical juncture for BriaCell. As off-the-shelf personalized cancer vaccines, they represent an innovative approach in the oncology field. The 'off-the-shelf' component indicates that these vaccines are readily available and do not require individualized production for each patient, which could significantly reduce manufacturing times and costs. Meanwhile, the 'personalized' aspect implies that the vaccines are designed to work with the patient's immune system in a targeted manner.
It will be essential to evaluate the data on efficacy and safety from these trials to understand the vaccines' potential impact on patient outcomes. The ability to effectively treat advanced stages of breast and prostate cancer with fewer side effects could be a game-changer. Additionally, the scalability of Bria-OTS+ and Bria-PROS+ production could address a larger patient population if approved, making them highly significant in the therapeutic market for these cancers.
- Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell
PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.
“We are ecstatic about working with the team led by Dr. Pohlmann,” stated Dr. Williams, BriaCell’s President & CEO. “We strongly believe in the therapeutic potential of our novel personalized next-generation vaccine platform and this agreement will be invaluable to us as we advance the clinical development of our off-the-shelf therapies to those cancer patients with persistent unmet medical needs.”
“Through this agreement, we expect to further our understanding of our novel immunotherapy’s mechanism of action and its use in breast and prostate cancer patients,” stated Dr. Giuseppe Del Priore, BriaCell’s CMO. “Our shared goal is to improve the survival and quality of life in cancer patients who are fighting a disease with a poor prognosis and a short life expectancy.”
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those in relation to: whether the agreement with Dr. Pohlmann will advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively; whether the agreement will be invaluable to BriaCell as it advances the clinical development of its off-the-shelf therapies to those cancer patients with persistent unmet medical needs; and whether the agreement will further BriaCell’s understanding of its novel immunotherapy’s mechanism of action and its use in breast and prostate cancer patients; are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
What is the significance of the agreement between BriaCell and the leading cancer treatment group?
Who is Dr. Paula Pohlmann and what role does she play in the collaboration?
What are Bria-OTS+ and Bria-PROS+?
Which types of cancer are targeted by Bria-OTS+ and Bria-PROS+ vaccines?
